PH12013501779B1 - Pyrrolopyridines as kinase inhibitors - Google Patents
Pyrrolopyridines as kinase inhibitorsInfo
- Publication number
- PH12013501779B1 PH12013501779B1 PH12013501779A PH12013501779A PH12013501779B1 PH 12013501779 B1 PH12013501779 B1 PH 12013501779B1 PH 12013501779 A PH12013501779 A PH 12013501779A PH 12013501779 A PH12013501779 A PH 12013501779A PH 12013501779 B1 PH12013501779 B1 PH 12013501779B1
- Authority
- PH
- Philippines
- Prior art keywords
- pyrrolopyridines
- kinase inhibitors
- compounds
- formula
- chkl
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 150000005255 pyrrolopyridines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 101150006084 CHKB gene Proteins 0.000 abstract 1
- 101000777277 Homo sapiens Serine/threonine-protein kinase Chk2 Proteins 0.000 abstract 1
- 102100031075 Serine/threonine-protein kinase Chk2 Human genes 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000011065 in-situ storage Methods 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5292608P | 2008-05-13 | 2008-05-13 | |
| PCT/US2009/043691 WO2009140320A1 (en) | 2008-05-13 | 2009-05-13 | Pyrrolopyridines as kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PH12013501779A1 PH12013501779A1 (en) | 2014-08-27 |
| PH12013501779B1 true PH12013501779B1 (en) | 2019-02-13 |
Family
ID=40810786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12013501779A PH12013501779B1 (en) | 2008-05-13 | 2013-08-28 | Pyrrolopyridines as kinase inhibitors |
Country Status (30)
| Country | Link |
|---|---|
| US (6) | US8178131B2 (enExample) |
| EP (2) | EP2990407B1 (enExample) |
| JP (2) | JP5703212B2 (enExample) |
| KR (2) | KR101657856B1 (enExample) |
| CN (3) | CN104926810B (enExample) |
| AR (1) | AR071717A1 (enExample) |
| AU (1) | AU2009246402B2 (enExample) |
| BR (1) | BRPI0913580B8 (enExample) |
| CA (1) | CA2724262C (enExample) |
| CL (1) | CL2009001152A1 (enExample) |
| CO (1) | CO6321244A2 (enExample) |
| CR (1) | CR11803A (enExample) |
| CY (1) | CY1116692T1 (enExample) |
| DK (1) | DK2307409T3 (enExample) |
| ES (1) | ES2552643T3 (enExample) |
| HK (1) | HK1219950A1 (enExample) |
| HR (1) | HRP20151018T1 (enExample) |
| HU (1) | HUE026160T2 (enExample) |
| IL (1) | IL209258A (enExample) |
| MX (1) | MX2010012449A (enExample) |
| NZ (1) | NZ589318A (enExample) |
| PH (1) | PH12013501779B1 (enExample) |
| PL (1) | PL2307409T3 (enExample) |
| PT (1) | PT2307409E (enExample) |
| RS (1) | RS54358B1 (enExample) |
| RU (1) | RU2517194C2 (enExample) |
| SI (1) | SI2307409T1 (enExample) |
| TW (2) | TWI554512B (enExample) |
| UA (1) | UA111933C2 (enExample) |
| WO (1) | WO2009140320A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101959887B (zh) | 2008-01-08 | 2013-07-31 | 阵列生物制药公司 | 作为激酶抑制剂的吡咯并吡啶 |
| ES2392014T3 (es) | 2008-01-09 | 2012-12-03 | Array Biopharma, Inc. | Pirazolopiridinas como inhibidores de la cinasa |
| JP2009256298A (ja) * | 2008-03-26 | 2009-11-05 | Sumitomo Chemical Co Ltd | ピペリジン−３−イルカーバメート化合物の光学分割方法およびその中間体 |
| AR071717A1 (es) * | 2008-05-13 | 2010-07-07 | Array Biopharma Inc | Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer. |
| US8481557B2 (en) | 2009-04-11 | 2013-07-09 | Array Biopharma Inc. | Method of treatment using checkpoint kinase 1 inhibitors |
| BRPI1013920A2 (pt) * | 2009-04-11 | 2016-04-05 | Array Biopharma Inc | inibidores de ponto de checagem de quinase 1 para potencializar agentes de danificação de dna |
| TWI466885B (zh) | 2009-07-31 | 2015-01-01 | Japan Tobacco Inc | 含氮螺環化合物及其醫藥用途 |
| US9029359B2 (en) * | 2009-09-04 | 2015-05-12 | Biogen Idec Ma, Inc. | Heteroaryl Btk inhibitors |
| RU2563644C2 (ru) | 2010-08-20 | 2015-09-20 | Хатчисон Медифарма Лимитед | Пирролопиримидиновые соединения и их применения |
| RU2627841C2 (ru) | 2010-11-16 | 2017-08-14 | Эррэй Биофарма Инк. | Комбинация ингибиторов чекпойнт-киназы 1 и ингибиторов киназы wee 1 |
| RU2598846C2 (ru) | 2011-02-25 | 2016-09-27 | Эррэй Биофарма Инк. | Триазолопиридиновые соединения как ингибиторы киназы pim |
| CA2834166A1 (en) | 2011-04-29 | 2012-11-01 | Amgen Inc. | Bicyclic pyridazine compounds as pim inhibitors |
| GB201201566D0 (en) | 2012-01-30 | 2012-03-14 | Vernalis R&D Ltd | New chemical compounds |
| CA2871436C (en) | 2012-04-23 | 2020-07-28 | Genentech, Inc. | Intermediates and processes for preparing compounds for use as chk1 inhibitors |
| US9993460B2 (en) | 2013-07-26 | 2018-06-12 | Race Oncology Ltd. | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof |
| EP3036227B1 (en) * | 2013-08-22 | 2020-01-08 | Genentech, Inc. | Process for preparing a compound |
| WO2015027090A1 (en) * | 2013-08-22 | 2015-02-26 | Genentech, Inc. | Intermediates and processes for preparing compounds |
| RU2018142605A (ru) * | 2013-09-25 | 2019-02-04 | Вертекс Фармасьютикалз Инкорпорейтед | Селективный ингибитор фосфатидилинозитол-3-киназы-гамма |
| JP6783224B2 (ja) | 2014-04-04 | 2020-11-11 | デル マー ファーマシューティカルズ | 肺の非小細胞癌腫及び卵巣癌を処置するためのジアンヒドロガラクチトール及びその類縁体又は誘導体の使用 |
| AR101106A1 (es) | 2014-07-02 | 2016-11-23 | Pharmacyclics Llc | Inhibidores de tirosina quinasa de bruton |
| MA41599A (fr) * | 2015-02-26 | 2018-01-02 | Array Biopharma Inc | Formes cristallines d'un composé pyrrolopyridine |
| WO2017003090A1 (ko) | 2015-06-30 | 2017-01-05 | 서울바이오시스 주식회사 | Uv led가 적용된 포충기 |
| CA3001735A1 (en) | 2015-11-04 | 2017-05-11 | Merck Patent Gmbh | Methods for treating cancer using pyrimidine and pyridine compounds with btk inhibitory activity |
| MX2018007703A (es) * | 2015-12-22 | 2018-11-09 | Vitae Pharmaceuticals Inc | Inhibidores de la interaccion de menina-linaje leucemico mixto. |
| HRP20201771T1 (hr) | 2016-06-10 | 2021-02-19 | Vitae Pharmaceuticals, Llc | Inhibitori interakcije menin-mll |
| EP3461480A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer |
| MA52809A (fr) | 2018-06-07 | 2021-04-14 | Disarm Therapeutics Inc | Inhibiteurs de sarm1 |
| TWI873098B (zh) | 2018-07-03 | 2025-02-21 | 瑞士商諾華製藥公司 | 用於治療與sting活性相關之病症的化合物及組合物 |
| CN108912032A (zh) * | 2018-08-13 | 2018-11-30 | 南通大学 | 一种（3s，4r）-4-甲基吡咯烷-3-基氨基甲醇叔丁酯盐酸盐的化学合成方法 |
| CN109053526A (zh) * | 2018-08-13 | 2018-12-21 | 南通大学 | 一种（3r，4s）-4-甲基吡咯烷-3-基氨基甲酸叔丁酯盐酸盐的化学合成方法 |
| US12083114B2 (en) | 2018-12-19 | 2024-09-10 | Disarm Therapeutics, Inc. | Inhibitors of SARM1 in combination with neuro-protective agents |
| WO2020150417A2 (en) | 2019-01-17 | 2020-07-23 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| JP2023540673A (ja) | 2020-07-15 | 2023-09-26 | アイエフエム デュー インコーポレイテッド | Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物 |
| EP4274824A1 (en) | 2021-01-08 | 2023-11-15 | IFM Due, Inc. | Heterobicyclic compounds having an urea or analogue and their compositions for treating conditions associated with sting activity |
| AU2022274325A1 (en) | 2021-05-14 | 2023-10-05 | Syndax Pharmaceuticals, Inc. | Inhibitors of the menin-mll interaction |
| PE20240931A1 (es) | 2021-08-10 | 2024-04-30 | Ifm Due Inc | Compuestos y composiciones para tratar condiciones asociadas con actividad de sting |
| CN119798252A (zh) * | 2023-10-09 | 2025-04-11 | 中国石油化工股份有限公司 | 一种制备n邻位-酰基取代的含氮杂环化合物及其缩胺合铁(ii)配合物的方法 |
| WO2025260014A1 (en) * | 2024-06-14 | 2025-12-18 | Tenvie Therapeutics, Inc. | Compounds, compositions, and methods |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995010519A1 (en) | 1993-10-14 | 1995-04-20 | Abbott Laboratories | Quinolizinone type compounds |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| WO2001058869A2 (en) | 2000-02-11 | 2001-08-16 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases |
| AU2001249865A1 (en) | 2000-04-18 | 2001-10-30 | Agouron Pharmaceuticals, Inc. | Pyrazoles for inhibiting protein kinase |
| AU2002336462A1 (en) | 2001-09-06 | 2003-03-24 | Millennium Pharmaceuticals, Inc. | Piperazine and homopiperazine compounds |
| WO2003028724A1 (en) | 2001-10-04 | 2003-04-10 | Smithkline Beecham Corporation | Chk1 kinase inhibitors |
| US6797825B2 (en) | 2001-12-13 | 2004-09-28 | Abbott Laboratories | Protein kinase inhibitors |
| TWI329112B (en) | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
| EP1537106A1 (en) | 2002-08-07 | 2005-06-08 | Mitsubishi Pharma Corporation | Dihydropyrazolopyridine compounds |
| US20050256157A1 (en) | 2002-08-23 | 2005-11-17 | Chiron Corporation | Combination therapy with CHK1 inhibitors |
| US8580782B2 (en) | 2002-09-04 | 2013-11-12 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
| AR042667A1 (es) | 2002-12-26 | 2005-06-29 | Taisho Pharmaceutical Co Ltd | Derivados de pirrolopirimidina y pirrolopiridina sustituidos con un grupo amino ciclico |
| US20070149560A1 (en) | 2003-03-14 | 2007-06-28 | Astrazeneca Ab | Novel fused triazolones and the uses thereof |
| GB0308208D0 (en) * | 2003-04-09 | 2003-05-14 | Glaxo Group Ltd | Chemical compounds |
| GB0330042D0 (en) * | 2003-12-24 | 2004-01-28 | Pharmacia Italia Spa | Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them |
| GB0330043D0 (en) | 2003-12-24 | 2004-01-28 | Pharmacia Italia Spa | Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them |
| MXPA06011328A (es) * | 2004-04-02 | 2006-12-15 | Vertex Pharma | Azaindoles utiles como inhibidotes de roca y otras proteinas cinasas. |
| US7745436B2 (en) * | 2004-04-13 | 2010-06-29 | Synta Pharmaceuticals Corporation | Disalt inhibitors of IL-12 production |
| GB0409080D0 (en) | 2004-04-23 | 2004-05-26 | Biofocus Discovery Ltd | Compounds which interact with protein kinases |
| JP2007161585A (ja) | 2004-06-25 | 2007-06-28 | Taisho Pharmaceut Co Ltd | 環状アミノ基で置換されているピロロピリミジン及びピロロピリジン誘導体 |
| UY29177A1 (es) | 2004-10-25 | 2006-05-31 | Astex Therapeutics Ltd | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos |
| GB0501999D0 (en) | 2005-02-01 | 2005-03-09 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| JP2008534664A (ja) | 2005-04-06 | 2008-08-28 | アストラゼネカ アクチボラグ | 置換複素環およびｃｈｋ１、ｐｄｋ１及びｐａｋ阻害剤としてのそれらの使用 |
| EP2354139A1 (en) * | 2005-05-20 | 2011-08-10 | Vertex Pharmaceuticals Incorporated | Pyrrolopyridines useful as inhibitors of protein kinase |
| BRPI0614974A2 (pt) * | 2005-08-30 | 2010-12-14 | Asahi Kasei Pharma Corp | composto, medicamento, inibidor da fosforilaÇço da cadeia leve regulatària da miosina, inibidor da via rho/rho quinase, e, mÉtodo para tratamento terapÊutico e/ou profilÁtico de glaucoma |
| AR056206A1 (es) | 2005-10-06 | 2007-09-26 | Schering Corp | Pirazolpirimidinas como inhibidores de protein quinasas |
| WO2007044441A2 (en) | 2005-10-06 | 2007-04-19 | Schering Corporation | Use of pyrazolo [1 , 5 -a] pyrimidine derivatives for inhibiting protein kinases methods for inhibiting protein kinases |
| PT2474545T (pt) | 2005-12-13 | 2017-02-14 | Incyte Holdings Corp | Pirrolo[2,3-b]piridinas e pirrolo[2,3-b]pirimidinas substituídas com heteroarilo como inibidores de janus quinase |
| JP2009523812A (ja) | 2006-01-19 | 2009-06-25 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | 融合へテロ二環式キナーゼ阻害剤 |
| DE102006005180A1 (de) | 2006-02-06 | 2007-08-09 | Merck Patent Gmbh | Indazol-heteroaryl-derivate |
| DE102006005179A1 (de) | 2006-02-06 | 2007-08-09 | Merck Patent Gmbh | Aminoindazolderivate |
| EP2016077A2 (en) | 2006-04-25 | 2009-01-21 | Astex Therapeutics Limited | Pharmaceutical compounds |
| WO2007125310A2 (en) | 2006-04-25 | 2007-11-08 | Astex Therapeutics Limited | Pharmaceutical combinations of pk inhibitors and other active agents |
| EP3719018B1 (en) * | 2006-04-25 | 2025-08-27 | Astex Therapeutics Ltd | Purine and deazapurine derivatives as pharmaceutical compounds |
| WO2008012635A2 (en) * | 2006-07-26 | 2008-01-31 | Pfizer Products Inc. | Amine derivatives useful as anticancer agents |
| WO2008075007A1 (en) | 2006-12-21 | 2008-06-26 | Cancer Research Technology Limited | Morpholino-substituted bicycloheteroaryl compounds and their use as anti cancer agents |
| BRPI0808523A2 (pt) | 2007-03-01 | 2014-08-19 | Novartis Vaccines & Diagnostic | Inibidores de pim cinase e métodos de seu uso |
| WO2009004329A1 (en) | 2007-07-02 | 2009-01-08 | Cancer Research Technology Limited | 9h-pyrimido[4,5-b]indoles, 9h-pyrido[4',3':4,5]pyrrolo[2,3-d]pyridines, and 9h-1,3,6,9-tetraaza-fluorenes as chk1 kinase function inhibitors |
| CN101903396A (zh) | 2007-11-07 | 2010-12-01 | 先灵公司 | 新的细胞周期关卡调节剂和它们与关卡激酶抑制剂的联合应用 |
| CN101959887B (zh) * | 2008-01-08 | 2013-07-31 | 阵列生物制药公司 | 作为激酶抑制剂的吡咯并吡啶 |
| ES2392014T3 (es) | 2008-01-09 | 2012-12-03 | Array Biopharma, Inc. | Pirazolopiridinas como inhibidores de la cinasa |
| AR071717A1 (es) | 2008-05-13 | 2010-07-07 | Array Biopharma Inc | Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer. |
| US8481557B2 (en) * | 2009-04-11 | 2013-07-09 | Array Biopharma Inc. | Method of treatment using checkpoint kinase 1 inhibitors |
| US20140221370A1 (en) | 2010-07-09 | 2014-08-07 | Array Biopharma Inc. | Pyrrolopyridines as kinase inhibitors |
| RU2627841C2 (ru) | 2010-11-16 | 2017-08-14 | Эррэй Биофарма Инк. | Комбинация ингибиторов чекпойнт-киназы 1 и ингибиторов киназы wee 1 |
-
2009
- 2009-05-12 AR ARP090101708A patent/AR071717A1/es active IP Right Grant
- 2009-05-12 CL CL2009001152A patent/CL2009001152A1/es unknown
- 2009-05-13 RU RU2010150786/04A patent/RU2517194C2/ru active
- 2009-05-13 KR KR1020147015705A patent/KR101657856B1/ko not_active Expired - Fee Related
- 2009-05-13 CA CA2724262A patent/CA2724262C/en active Active
- 2009-05-13 HR HRP20151018TT patent/HRP20151018T1/hr unknown
- 2009-05-13 ES ES09747404.3T patent/ES2552643T3/es active Active
- 2009-05-13 US US12/992,468 patent/US8178131B2/en active Active
- 2009-05-13 MX MX2010012449A patent/MX2010012449A/es active IP Right Grant
- 2009-05-13 JP JP2011509628A patent/JP5703212B2/ja not_active Expired - Fee Related
- 2009-05-13 AU AU2009246402A patent/AU2009246402B2/en not_active Ceased
- 2009-05-13 CN CN201510289964.7A patent/CN104926810B/zh not_active Expired - Fee Related
- 2009-05-13 PT PT97474043T patent/PT2307409E/pt unknown
- 2009-05-13 RS RS20150711A patent/RS54358B1/sr unknown
- 2009-05-13 EP EP15175131.0A patent/EP2990407B1/en active Active
- 2009-05-13 KR KR1020107027941A patent/KR101643426B1/ko not_active Expired - Fee Related
- 2009-05-13 CN CN201910068067.1A patent/CN109942575A/zh active Pending
- 2009-05-13 WO PCT/US2009/043691 patent/WO2009140320A1/en not_active Ceased
- 2009-05-13 EP EP09747404.3A patent/EP2307409B1/en active Active
- 2009-05-13 PL PL09747404T patent/PL2307409T3/pl unknown
- 2009-05-13 UA UAA201015012A patent/UA111933C2/uk unknown
- 2009-05-13 HU HUE09747404A patent/HUE026160T2/en unknown
- 2009-05-13 TW TW103133772A patent/TWI554512B/zh not_active IP Right Cessation
- 2009-05-13 NZ NZ589318A patent/NZ589318A/en not_active IP Right Cessation
- 2009-05-13 DK DK09747404.3T patent/DK2307409T3/en active
- 2009-05-13 CN CN200980127299.4A patent/CN102089307B/zh not_active Expired - Fee Related
- 2009-05-13 SI SI200931284T patent/SI2307409T1/sl unknown
- 2009-05-13 TW TW098115906A patent/TWI458727B/zh not_active IP Right Cessation
- 2009-05-13 BR BRPI0913580A patent/BRPI0913580B8/pt not_active IP Right Cessation
-
2010
- 2010-11-11 IL IL209258A patent/IL209258A/en active IP Right Grant
- 2010-11-19 CR CR11803A patent/CR11803A/es unknown
- 2010-11-30 CO CO10150963A patent/CO6321244A2/es active IP Right Grant
-
2012
- 2012-03-20 US US13/425,186 patent/US8545897B2/en not_active Expired - Fee Related
-
2013
- 2013-08-23 US US13/974,895 patent/US8758830B2/en active Active
- 2013-08-28 PH PH12013501779A patent/PH12013501779B1/en unknown
-
2014
- 2014-05-06 US US14/271,129 patent/US8981085B2/en active Active
-
2015
- 2015-01-07 US US14/591,691 patent/US9365568B2/en active Active
- 2015-02-23 JP JP2015032474A patent/JP2015098482A/ja not_active Withdrawn
- 2015-09-16 CY CY20151100812T patent/CY1116692T1/el unknown
-
2016
- 2016-01-05 US US14/988,521 patent/US9969727B2/en active Active
- 2016-07-08 HK HK16107983.6A patent/HK1219950A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12013501779A1 (en) | Pyrrolopyridines as kinase inhibitors | |
| SG178899A1 (en) | Raf inhibitor compounds and methods of use thereof | |
| SG178900A1 (en) | Raf inhibitor compounds and methods of use thereof | |
| WO2009111278A3 (en) | Raf inhibitor compounds and methods of use thereof | |
| MX2014005282A (es) | Compuestos de 8-fluoroftalazin-1 (2h) -ona. | |
| TW200801012A (en) | Phosphoinositide 3-kinase inhibitor compounds and methods of use | |
| MX2010002543A (es) | Combinaciones de compuestos inhibidores de fosfoinosituro 3-cinasa y agentes quimioterapeuticos, y metodos de uso. | |
| MX2014014828A (es) | Compuestos de 5-azaindazol y metodos de uso. | |
| TW200800996A (en) | Heterobicyclic pyrazole compounds and methods of use | |
| WO2007127175A3 (en) | Pharmaceutical compounds | |
| MX2011009167A (es) | Combinaciones de compuestos inhibidores de fosfoinositida 3-cinasa y agentes quimioterapeuticos para el tratamiento contra neoplasia hemotopoyeticas malignas. | |
| PH12014500966A1 (en) | Alkylated piperazine compounds as inhibitors of btk activity | |
| MY160349A (en) | Pyridone and aza-pyridone compounds and methods of use | |
| MX2011012520A (es) | Compuestos inhibidores de pi3k de pirimidina biciclicos selectivos para p110 delta y metodos de uso de los mismos. | |
| MX340013B (es) | Compuestos de benzoxazepina selectivos para fosfatidilinositol 3-cinasa (pi3k) p110 delta y metodos de uso. | |
| MX2014005285A (es) | Compuestos biciclicos de piperazina. | |
| WO2007146824A3 (en) | Quinoline compounds and methods of use | |
| UA116774C2 (uk) | Інгібітори серин/треонінкінази | |
| SG178986A1 (en) | 4-substituted pyridin-3-yl-carboxamide compounds and methods of use | |
| PH12012500608A1 (en) | Benzoxepin pi3k inhibitor compounds and methods of use | |
| UA111756C2 (uk) | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона | |
| MX2010010659A (es) | Compuestos de benzopirano y benzoxepina, inhibidores de fosfoinoinositida 3-cinasas y metodos para utilizarlos. | |
| MX2014001239A (es) | Compuestos de pirazolo [3,4-c] piridina y metodos de uso. | |
| PH12012501864A1 (en) | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | |
| WO2008028141A3 (en) | Raf inhibitor compounds and methods of use thereof |